Q2 2025 Earnings Call Transcript August 11, 2025 BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.4, ...

Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported ...

FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong ...

Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial ...

Kula approaches impact investing as a critical avenue to build the future of worldwide communities, starting with the ...

Key Points Net product revenue (GAAP) rose 11% to $24.2 million, Net product revenue exceeded analyst estimates by $1.063 million (GAAP), rising 11% to $24.2 million. GAAP net loss per share widened ...

ZUSDURITM (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent lo ...

On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved ZUSDURI (formerly UGN-102), the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC.

The best portable grills deliver all the smoky, seared-up goodness of a full-size barbecue in a smaller, more travel-friendly ...

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ...

How does your 401(k) compare to the average worker's? Is it time to buy small-cap stocks? What you should do with any "raise" ...